About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT05042973

The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

The aim of this trial is to assess the effect of Empagliflozin on lipid and glucose metabolism as well as volume homeostasis and renal function in elderly and obese patients with increased risk of dev...

Lead sponsor: Jacob Moller•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Jacob Moller

Collaborators

Danish Heart Foundation
Herlev and Gentofte Hospital
University Hospital Bispebjerg and Frederiksberg
Hillerod Hospital, Denmark
Rigshospitalet, Denmark

The Empire Prevent: Metabolic is a part of the Empire Prevent Trial Program, which also comprises the Empire Prevent: Cardiac. The Empire Prevent: Metabolic is designed to enroll at least 120 patients.

Age

60 - 84 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Body mass index \>28kg/m2
•Age 60-84 years
•Established risk factor for developing heart failure, defined as at least one of the following:
•hypertension
•ischemic heart disease
•stroke/transient cerebral ischemia
•chronic kidney disease (eGFR 30-45ml/min/1.73m2)

Exclusion Criteria

•Diabetes mellitus type 1 or 2 (no medical history, no antidiabetic treatment)
•Heart failure with reduced ejection fraction (LVEF \<40%)
•Inability to perform exercise test
•Dementia
•Severe non-compliance
•Substance abuse
•Severe chronic obstructive pulmonary disease (FEV1\<50% expected value)
•Permanent atrial fibrillation
•GFR \<30 ml/min/1,73m2
•Severe peripheral artery disease
•Cancer treatment within one year beside prostate cancer and basal cell carcinoma
•Severe aortic or mitral valve disease
•Pregnancy or breastfeeding
•Acute hospital admission within 30 days
•Participation in other pharmacological study

Related studies

Effect of Personalized Follow-up in Adapted Physical Activities in Subjects With Chronic Heart Failure.

NCT06222762 · Heart Failure

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss

NCT06894498 · Obesity and Obesity-related Medical Conditions, Weight Loss

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more

RECRUITINGPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades

NCT06052475 · Pacing-Induced Cardiomyopathy, Heart Failure

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 29, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment165

Start dateSep 2021

Last updatedJan 29, 2025

Condition

Obesity Heart Failure

Locations shown

Herlev Hospital

Herlev

Odense University Hospital

Odense

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions